Abstract:<h1>A Critical View of Specific Antibody Deficiencies</h1><a href="http://www.frontiersin.org/people/u/174823">Ricardo U. Sorensen</a>1,2,3*<ul><li>1Professor Emeritus of Pediatrics, Department of Pediatrics, Louisiana State University Health Science Center, New Orleans, LA, United States</li><li>2Louisiana Primary Immunodeficiency Network, New Orleans, LA, United States</li><li>3Honorary Professor, Faculty of Medicine, University of La Frontera, Temuco, Chile</li></ul>In thisopinion manuscript the author postulates that the present definition of Specific Antibody Deficiency (SAD) needs to be revised and expanded. It is presently defined as a syndrome of low IgG antibody responses to purified Streptococcus pneumoniae capsular polysaccharides vaccines with normal concentrations of IgG, IgA, IgM, and IgG subclasses. Responses to protein antigens and to pneumococcal polysaccharides conjugated to proteins are normal (<a href="#B1">1</a>, <a href="#B2">2</a>). Severe, moderate and memory SAD forms have been arbitrarily defined by expert committees. These definitions miss the imperfections of a diagnosis based on mainly poorly standardized laboratory tests and curtail the search for many other clinically relevant specific deficiencies of antibodies to bacterial, viral and fungal pathogens.<h2>The Laboratory Tests on Which the Diagnoses of SAD are Based are Variable and Imperfect</h2>The assessment of IgG antibodies against S. pneumonia serotype-specific capsular vaccine antigens are widely used to diagnose a patient's ability to develop IgG antibody responses. Available vaccines include a 23-valent purified capsular polysaccharide vaccine that includes the 23 most prevalent serotypes (PPV-23) and several polysaccharide-protein conjugated vaccines that include antibiotic resistant serotypes. These are a 7 serotypes vaccine (PCV-7) that was replaced by a 13 serotypes vaccine (PCV-13) and a different 10-valent vaccine (PCV-10). The use of both purified polysaccharide and combined protein-polysaccharide vaccines places evaluation of anti-pneumococcal immunity among the most valuable tools used to assess an important component of antibody-mediated immunity.Different laboratory methods are used to define normal and abnormal antibody responses. The diagnosis of SAD is given to patients older than 2 years with recurrent infections who fail to mount an arbitrarily defined normal response to purified pneumococcal serotypes (<a href="#B3">3</a>, <a href="#B4">4</a>). If the patient was immunized with PCV-7, PCV-13, or PCV-10, the diagnosis of SAD is only possible based on the response to serotypes not present in conjugate vaccines. A response to conjugated serotypes does not preclude unresponsiveness to pure polysaccharide antigens. Correlation of the extent of antibody deficiencies and clinical presentation is poor, the diagnostic methods used at the present time are unreliable, and having low responses as defined for SAD does not necessarily lead to recurrent infections (<a href="#B5">5</a>).The methods used to measure anti-pneumococcal, serotype-specific IgG antibodies that confer long-term protection are summarized in <a href="#T1">Table 1</a> (<a href="#B6">6</a>, <a href="#B7">7</a>).TABLE 1Table 1. Methods to measure lgG anti-S. pneumonia surface polysaccharide antibodies.The World Health Organization ELISA (WHO, ELISA) is well-standardized and reproducible. It defines a specific way of performing this test. It was developed under the auspices of the World Health Organization, to evaluate conjugate vaccine effectiveness. Results are expressed as μg/ml after calibration against an FDA standard now replaced by 007sp and by laboratory standards (<a href="#B7">7</a>).An easier to perform method that simultaneously measures antibodies to each of the 23 serotypes in the PPV-23 is based on a multiplex fluorescent bead assay, Luminex®. It is used by most reference laboratories in the United States. Luminex results are consistent within laboratories but there are significant differences among laboratories and its correlation with ELISA test results is variable (<a href="#B7">7</a>, <a href="#B8">8</a>).A “global test” measures antibodies against all 23 serotypes in the 23-valent PPV as one antigen (<a href="#B9">9</a>). The information obtained with the global test does not correlate well with results obtained when measuring antibodies against each serotype individually.The only functional assay of anti-pneumococcal antibodies is opsonophagocytosis (OPA). It measures antibodies of all immunoglobulin classes against polysaccharide and protein antigens on the surface of intact bacteria. This test is not generally available for clinical use although vaccine manu-Abstract Truncated-

Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency

Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects

Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine

Pneumococcal antibody response in children with recurrent respiratory tract infections: A descriptive study

A Critical View of Specific Antibody Deficiencies

Quantitative determination of C-polysaccharide in Streptococcus pneumoniae capsular polysaccharides by enzyme-linked immunosorbent assay

Identification and Quantification of a Pneumococcal Cell Wall Polysaccharide by Antibody-Enhanced Chromatography Assay

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Polysaccharide and conjugate vaccines to Streptococcus pneumoniae generate distinct humoral responses

Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

Serotype-specific quantification of residual free polysaccharide in multivalent pneumococcal conjugate vaccines

Secondary Immunodeficiency and Vaccine Response in Rheumatoid and Psoriatic Arthritis on Immunosuppressive Medicines

Development and validation of carbodiimide-activated ELISA plate for quantifying IgG levels against Streptococcus pneumoniae capsular polysaccharides

Estimating the serotype-specific association between the concentration of vaccine-induced serum antibodies and protection against pneumococcal colonization

Antibody responses after sequential vaccination with PCV13 and PPSV23 in patients with moderate to severe plaque psoriasis under immunosuppressive therapy

Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional Streptococcus pneumoniae Serotype–specific Polysaccharides in Human Urine

Evaluation of Acute and Convalescent Antibody Concentration Against Pneumococcal Capsular Polysaccharides for the Diagnosis of Pneumococcal Infection in Children with Community-Acquired Pneumonia

Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children

Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study